Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AC-OLE-06 is an investigational liquid formulation of tricaprilin (glyceryl trioctanoate), a medium-chain triglyceride (MCT) being developed by Cerecin for the treatment of Alzheimer's disease. Tricaprilin acts as a ketogenic precursor; upon oral administration, it is hydrolyzed in the gastrointestinal tract and metabolized by the liver into ketone bodies, such as beta-hydroxybutyrate. These ketone bodies cross the blood-brain barrier and serve as an alternative energy source for neurons in patients with Alzheimer's disease, whose brains often exhibit impaired glucose metabolism (cerebral hypometabolism). AC-OLE-06 is part of a series of optimized 'OLE' (oil-based) formulations designed to enhance the pharmacokinetic profile and improve gastrointestinal tolerability compared to earlier MCT-based products like AC-1202 (Axona).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AC-OLE-06.